ImmunoCellular Therapeutics Elects Dr. Navdeep Jaikaria to Board of Directors

Jaikaria is Former Award-Winning Analyst for Picking Biotech
Stocks
LOS ANGELES--(Business Wire)--
ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) (IMUC), a
biotechnology company, announced today that Navdeep Jaikaria, Ph.D.,
former managing director of equity research and senior biotechnology
analyst at Rodman & Renshaw, has been elected to the company's board
of directors.

"Dr. Jaikaria brings a wealth of knowledge to IMUC, and we are
pleased in his eagerness to commit himself as a board member of IMUC
as well, given that he was named one of the five best stock-pickers in
biotechnology in the Wall Street Journal's annual "Best on the Street"
Analysts survey in 2007," stated Manish Singh, Ph.D., president and
chief executive officer of IMUC. "Navdeep is a strong addition to our
board of directors and will be able to provide among other things, the
Wall Street perspective, as we look to raise our profile with key
biotechnology investors and analysts in the coming months and years."

"I am excited to join this talented board of directors and believe
that the data I have seen from IMUC's cancer vaccines and cancer stem
cell vaccines thus far, demonstrate significant potential for these
drug candidates," stated Dr. Jaikaria. "IMUC is targeting large
markets with both its cancer vaccines and monoclonal antibody
technologies with the hope of providing less toxic or rigorous
treatment alternatives for patients with multiple types of cancer
including glioblastoma, lung cancer and pancreatic cancer."

Navdeep Jaikaria, Ph.D., brings a wide variety of experience to
IMUC's board of directors with an emphasis on the Wall Street
perspective. Dr. Jaikaria recently retired from Rodman & Renshaw where
he was a senior equity research analyst covering approximately 30
companies across multiple therapeutic classes. He was named one of the
five best stock-pickers in biotechnology in the Wall Street Journal's
"Best on the Street" analysts survey in 2007. He has consistently been
ranked as a top analyst and as high as number three by Starmine on the
basis of portfolio returns for 2006. Dr. Jaikaria was with Rodman &
Renshaw from 2003 to 2008 and held positions in equity research with
Leerink Swann and Mehta Partners prior to that. Before joining Wall
Street, he also served as a consultant to pharmaceutical and
biotechnology companies. He has provided input to the U.S. Senate
Health Committee on Biodefense issues and has been widely cited in
national and international print and broadcast media including the
Wall Street Journal, Financial Times, CNN and CNBC. Dr. Jaikaria holds
a Ph.D. in Cell Biology and Anatomy from New York Medical College,
conducted a research fellowship at The Rockefeller University and
holds a B.S. in Human Biology from All India Institute of Medical
Sciences.

About ImmunoCellular Therapeutics

IMUC is a Los Angeles-based clinical-stage company that is
developing immune based therapies for the treatment of brain and other
cancers. IMUC's lead product candidate--a dendritic cell-based vaccine
for treating brain tumors--is currently being evaluated in a Phase I
clinical trial. Additionally, the company is developing a therapeutic
vaccine targeting cancer stem cells for multiple cancer indications
and is also evaluating its platform technology for monoclonal antibody
discovery using differential immunization for diagnosing and treating
multiple types of cancer. To learn more about IMUC, please visit
www.imuc.com.

Forward-Looking Statements

This press release contains certain forward-looking statements
that are subject to a number of risks and uncertainties, including
without limitation the risks associated with adhering to projected
preclinical or clinical timelines and the uncertainties of outcomes of
development work for product candidates; the need for substantial
additional capital to fund development of product candidates beyond
their initial clinical or pre-clinical stages; the risks associated
with obtaining and maintaining patent protection for vaccine and
antibody product candidates and the lack of patent coverage for the
differential immunization platform discovery technology; and the risk
of the ability to retain and recruit senior management personnel.
Additional risks and uncertainties are described in IMUC's most
recently filed SEC documents, such as its most recent annual report on
Form 10-KSB, all quarterly reports on Form 10-Q and any current
reports on Form 8-K. IMUC undertakes no obligation to publicly update
or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.

ImmunoCellular Therapeutics, Ltd.
Jennifer Cook Williams
Investor Relations
360-668-3701

Copyright Business Wire 2008